Spruce Street Capital LP Takes Position in Centessa Pharmaceuticals PLC Sponsored ADR $CNTA

Spruce Street Capital LP bought a new stake in Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) in the 4th quarter, HoldingsChannel.com reports. The firm bought 77,997 shares of the company’s stock, valued at approximately $1,951,000. Centessa Pharmaceuticals makes up approximately 0.6% of Spruce Street Capital LP’s investment portfolio, making the stock its 23rd largest holding.

Other large investors have also modified their holdings of the company. TD Waterhouse Canada Inc. acquired a new position in shares of Centessa Pharmaceuticals in the 4th quarter valued at $25,000. Caitong International Asset Management Co. Ltd acquired a new position in shares of Centessa Pharmaceuticals in the 4th quarter valued at $36,000. Wells Fargo & Company MN boosted its holdings in shares of Centessa Pharmaceuticals by 42.4% in the 4th quarter. Wells Fargo & Company MN now owns 3,387 shares of the company’s stock valued at $85,000 after buying an additional 1,008 shares in the last quarter. Knott David M Jr acquired a new position in shares of Centessa Pharmaceuticals in the 4th quarter valued at $100,000. Finally, Mirae Asset Global Investments Co. Ltd. boosted its holdings in shares of Centessa Pharmaceuticals by 26.4% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,688 shares of the company’s stock valued at $117,000 after buying an additional 979 shares in the last quarter. Institutional investors and hedge funds own 82.01% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have recently issued reports on CNTA. Truist Financial cut shares of Centessa Pharmaceuticals from a “buy” rating to a “hold” rating and set a $38.00 target price for the company. in a report on Monday, April 13th. B. Riley Financial cut shares of Centessa Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Tuesday, March 31st. Stephens cut shares of Centessa Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, March 31st. Wolfe Research cut shares of Centessa Pharmaceuticals from an “outperform” rating to a “hold” rating in a research note on Tuesday, March 31st. Finally, Needham & Company LLC cut shares of Centessa Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, March 31st. Four analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Centessa Pharmaceuticals currently has a consensus rating of “Hold” and an average price target of $41.33.

Centessa Pharmaceuticals Stock Up 0.1%

Shares of NASDAQ:CNTA opened at $39.76 on Tuesday. The stock has a market cap of $6.15 billion, a P/E ratio of -22.21 and a beta of 1.11. The firm has a fifty day moving average price of $39.64 and a 200 day moving average price of $30.96. The company has a debt-to-equity ratio of 0.23, a current ratio of 9.53 and a quick ratio of 9.53. Centessa Pharmaceuticals PLC Sponsored ADR has a 1-year low of $12.05 and a 1-year high of $40.26.

Centessa Pharmaceuticals (NASDAQ:CNTA) last issued its quarterly earnings results on Tuesday, May 5th. The company reported ($0.52) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.14). Sell-side analysts predict that Centessa Pharmaceuticals PLC Sponsored ADR will post -1.65 EPS for the current year.

Insiders Place Their Bets

In other Centessa Pharmaceuticals news, insider Karen M. Anderson sold 41,076 shares of the company’s stock in a transaction on Thursday, March 26th. The shares were sold at an average price of $30.12, for a total transaction of $1,237,209.12. Following the completion of the transaction, the insider owned 62,085 shares in the company, valued at approximately $1,870,000.20. This represents a 39.82% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 4.09% of the stock is currently owned by corporate insiders.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc is a global clinical‐stage biopharmaceutical company focused on the discovery and development of innovative therapies across multiple disease areas. The company operates a modular R&D network, bringing together a portfolio of independent, specialist research entities under a single corporate umbrella. This structure is designed to accelerate decision‐making and resource allocation while leveraging deep scientific expertise in each therapeutic domain.

Centessa’s pipeline spans oncology, immunology, neuroscience, cardiovascular and metabolic diseases, as well as rare genetic disorders.